Hosted on MSN
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
CEO Vincent Angotti highlighted significant progress in the NEPHRO CRRT study, emphasizing the FDA-approved reduction in study size from 166 to 70 patients while maintaining 90% statistical power for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback